CRL
Charles River Laboratories International, Inc.
CRL trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over CRL overall, supported by stronger valuation and stronger fundamentals.
CRL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Weak |
CRL's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $21.43 | -94% |
| Fair | 29x | $27.64 | -92% |
| Expensive | 46x | $44.08 | -87% |
| Current | 355x | $341 | — |
Historical ranges are pointers, not guarantees.
CRL's PE is in its expensive range at 355x.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over CRL in the historical PE scenario, which offers more potential upside but is not a forecast.
CRL Forward outlook
There aren't enough analyst estimates for CRL to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CRL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.96 | +$2.47 |
| Q2 2026 | -$4.80 | -$3.52 |
| Q1 2026 | -$3.71 | -$3.11 |
| Q4 2025 | -$2.91 | -1555% |
| Q3 2025 | -$1.51 | -119% |
| Q2 2025 | -$1.28 | -115% |
| Q1 2025 | -$0.60 | -107% |
| Q4 2024 | $0.20 | -98% |
CRL has returned to profit: it earned $0.96 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRL on earnings, with more consistent year-over-year improvement.
CRL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $982.7M | -2.2% |
| Q2 2026 | $1B | -2.7% |
| Q1 2026 | $995.8M | +1.2% |
| Q4 2025 | $994.2M | -0.8% |
| Q3 2025 | $1B | -0.5% |
| Q2 2025 | $1B | +0.6% |
| Q1 2025 | $984.2M | -2.7% |
| Q4 2024 | $1B | -1.1% |
CRL's revenue grew through 2022 and has held roughly level since: $983M last quarter, down 2.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +7.3 points |
| Q2 2026 | 12% | +2.2 points |
| Q1 2026 | 12% | +4.4 points |
| Q4 2025 | -29% | -12 points |
| Q3 2025 | 13% | +1.7 points |
| Q2 2025 | 9.7% | -5.1 points |
| Q1 2025 | 7.6% | -4.9 points |
| Q4 2024 | -17% | -30 points |
CRL's operating margin was 21% last quarter, up 7.3 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CRL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CRL on profitability, with a higher operating margin.
CRL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $207.3M | +16% |
| Q2 2026 | $148.6M | -12% |
| Q1 2026 | -$14.8M | -113% |
| Q4 2025 | $58.6M | -30% |
| Q3 2025 | $178.2M | -16% |
| Q2 2025 | $169.3M | +9.9% |
| Q1 2025 | $112.4M | +121% |
| Q4 2024 | $83.7M | -41% |
CRL still generates free cash flow, though less than at its 2024 peak: $400M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CRL on cash flow, with more consistent year-over-year improvement.
CRL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +563K shares |
| 1 year | -1.7% | -842K shares |
| 3 years | -5.9% | -3M shares |
| 5 years | -5.8% | -3M shares |
| Available history | -2.2% | -1.1M shares |
CRL has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $224,000 |
| Q2 2026 | $115.6M |
| Q1 2026 | $208.3M |
| Q4 2025 | $96,000 |
| Q3 2025 | $93,000 |
| Q2 2025 | $7.4M |
| Q1 2025 | $353.1M |
| Q4 2024 | $124,000 |
CRL spent $324M buying back its own shares over the past year, down 10% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.1x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 5.9x | High |
| Q4 2025 | 4.5x | High |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 3.9x | Elevated |
| Q1 2025 | 4.0x | Elevated |
| Q4 2024 | 3.5x | Elevated |
CRL's net debt is about 5.1 years of its operating earnings (EBITDA), up from 3.5 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over CRL on leverage, with a lower net debt burden relative to earnings.
CRL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.9 | Overbought |
| Stochastic | 75.1 | Neutral |
CRL's weekly RSI is 72 (overbought) and its Stochastic is 75 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRL PE vs Healthcare Sector
| Metric | CRL | Sector median | Relative |
|---|---|---|---|
| PE | 355x | 26x | 1,273% above |
| PE % | 96 | 29 | 67 pts above |
CRL is trading at 355x earnings, a 1273% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over CRL on valuation relative to its sector.
CRL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $321.0 | 6.2% above |
| 20 week MA | $284.7 | 20% above |
| 50 week MA | $223.9 | 52% above |
| 100 week MA | $191.1 | 78% above |
| 200 week MA | $201.5 | 69% above |
CRL has climbed back above all five of its weekly moving averages, and it's now 69% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
CRL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $151.9 | $251.7 | +66% |
| 2021 | $251.7 | $369.2 | +47% |
| 2022 | $369.2 | $218.5 | -41% |
| 2023 | $218.5 | $236.4 | +8.2% |
| 2024 | $236.4 | $186.2 | -21% |
| 2025 | $186.2 | $203.7 | +9.4% |
| 2026 YTD | $203.7 | $340.8 | +67% |
CRL has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.